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Abstract
Background Saline-filled intragastric balloons (IB) may be
inserted for 6 months to promote weight loss. We aimed to
assess potential benefits of repeating IB therapy.
Methods One hundred eighteen consecutive subjects (median
body mass index, 34.0 kg/m2; interquartile range [IQR],
31.2–36.9) treated with IB were included in a prospective
non-randomized multicenter study.
Results Nineteen (16%) subjects had repeat IB therapy at
their own request, either to prolong first treatment (n=8) or
after a IB-free interval (n=11). Higher weight loss 3 months
after first IB insertion independently predicted repeat
therapy (P=0.008). Median weight loss in subjects who
had repeat therapy was lower with second vs first IB (9.0 vs
14.6 kg; 30.4% vs 49.3% excess weight [EW]; P=0.003).
Compared to subjects with single treatment (n=99), those
with repeat treatment (n=19) had greater weight loss at
first IB extraction (14.6 vs 11.0 kg; 49.3% vs 30.7% EW;
P=0.026) and 1 year later (12.0 vs 6.0 kg; 40.9% vs
20.8% EW; P=0.008) but the difference became less than
2 kg starting at 3 years. At final follow-up (4.9 years; IQR,
3.4–6.7), the whole subject population had lost a median
of 2.0 kg (IQR, −3.0 to 10.3) or 6.2% EW (IQR, −8.1 to
31.6) and identical proportions of subjects with single/
repeat treatment had ≥10% baseline weight loss (26%) or
bariatric surgery (32%).
Conclusion Higher weight loss at 3 months indepen-
dently predicted repeat IB therapy; weight loss with the
second IB was lower compared to first IB. Repeat
treatment had no effect on proportions of subjects with
≥10% baseline weight loss or bariatric surgery at final
follow-up.
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Introduction
Three models of intragastric balloon (IB) are currently
available to promote weight loss in obese subjects [1]. The
liquid-filled Bioenterics IB is by far the most often used; it
decreases preprandial hunger, increases postprandial satiety
and promotes weight loss at short term [2–4]. The
manufacturer recommends removing the IB 6 months after
insertion, due to the risk of leakage after prolonged exposure
to gastric content and ensuing IB migration into the small
bowel. This 6-month period corresponds to the active weight
loss phase described in most weight loss programs [5];
during this period, the IB is thought allowing subjects to
modify their eating habits to favor long-term weight loss [6].
However, weight regain is common after IB removal.
Some subjects ask for repeat IB insertion, either at the
time of first IB removal (to prolong IB therapy beyond the
recommended 6-month period, in order to lose more weight
or to obtain more sustainable modifications of the eating
habits), or during follow-up after IB extraction (mainly to
treat weight regain). Intuitively, subjects who ask for repeat
IB insertion are those who made the most of initial IB
therapy (they are self-selected based on a high degree of
personal motivation and of IB-mediated effects such as
decreased hunger and early satiety).
We hypothesized that repeating IB therapy in self-
selected patients would allow to demonstrate that longer
IB therapy provides more weight loss at long term than the
standard 6-month treatment period.
We have prospectively followed a cohort of subjects for
a median of about 5 years after IB implantation for weight
loss; some of these received repeat IB therapy at their own
request. We analyze factors associated with repeat IB
therapy and compare long-term outcome in subjects who
received single vs repeat IB therapy.
Materials and Methods
Patients
Consecutive subjects who received an IB between June 25,
1999 and April 18, 2006 at Brussels (Belgium) or Geneva
(Switzerland) University Hospitals were included, after exclu-
sion of 13 subjects who had received an IB to induce weight
loss in order to facilitate bariatric surgery (n=9) or who were
lost to follow-up (n=4). Indications for IB treatment, contra-
indications, and work-up prior to IB insertion were as
previously described [1]. Insertion of a second IB was
performed if this option was requested by the patient, either
(1) as an extension of treatment, where the IB was replaced
with a new one during the same endoscopy session or (2) as a
repeat treatment, during follow-up. Neither option was
proposed to the patient by health care givers at our
institutions. Data collected prospectively included baseline
body height, weight and comorbidities, duration of IB therapy,
number of visits with the dietician, details of endoscopic
procedures, intake of a fiber-enriched, fat restricted, diet and
performance of moderate-intensity exercise ≥30 min daily
during IB therapy, potential complications, intake of weight
loss drugs, and body weights at 3, 6, 18 and 30 months after
first IB implantation as well as at an intermediary and final
follow-up (November 2007–January 2008 and January–
March 2009, respectively). In case of repeat IB insertion,
body weight was registered at the time of repeat IB insertion,
as well as 3 and 6 months later. The study complied with the
Declaration of Helsinki regarding investigation in humans and
was approved by the institutional ethics committees. This was
an investigator-initiated study with no industry involvement
in the design, conduct, funding, analysis of the results or
decision to submit the manuscript for publication.
Interventions
Only Bioenterics IBs (BIB™, Allergan, Irvine, CA, USA)
were implanted during the study period. Placement was
performed as previously described [4] and endoscopic IB
extraction (scheduled 6 months after implantation) was
immediately followed by upper gastrointestinal endoscopy
to detect potential lesions in all cases. In case of repeat IB
implantation, the IB was filled with 100 ml saline more
than for the first IB implantation. No structured weight-
maintenance program was proposed after IB extraction, but
subjects were strongly recommended to attend visits with
the dietician once a month for 6 months.
Definitions and Study Endpoints
The study population was divided in two groups of subjects,
i.e., subjects who received a single IB or those who had repeat
IB insertion, irrespective of the time of repeat IB insertion.
Ideal body weight was calculated according to the Lorentz
equation [7]. Weights at yearly intervals after the 30-month
follow-up were obtained by extrapolation using weights
recorded at intermediary and final follow-up. For subjects
who underwent bariatric surgery, body weight at the time of
operation was carried forward up to the end of follow-up
(last observation carried forward, or LOCF analysis). All
durations, including that of follow-up, were calculated since
insertion of the first IB except for Figs. 2 and 3.
The primary study endpoint was a comparison of weight
loss at yearly intervals in subjects treated with single vs
repeat IB insertion. Secondary endpoints included the
identification of factors associated with repeat IB therapy
and a comparison of first vs second IB therapy in terms of
weight loss and of associated morbidity.
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Statistical Analysis
All analyses were performed on an intention-to-treat basis
including all subjects. Continuous variables were described
by their medians with interquartile range (IQR) under
parentheses. Comparisons of continuous variables was
performed using ANOVA or the Kruskal–Wallis test if they
were found to be non-normally distributed after Shapiro–
Wilk normality test using a P value<0.05; comparisons of
continuous variables in identical subjects at different time
points were performed using the paired t test. Categorical
data were compared using the Fisher exact test (or the
McNemar’s test for comparison of complications in identical
subjects with the first vs the second IB). We also examined
which factors—including age, gender, baseline body mass
index (BMI), number of visits with the dietician during first
IB therapy, weight loss at 3 months, performance ofmoderate-
intensity exercise ≥30 min daily and intake of a fiber-
enriched, fat restricted diet during first IB therapy, duration
of treatment with the first IB and previous intake of weight
loss drugs—were associated with repeat IB therapy, using
stepwise logistic regression analysis. All tests were two-sided;
P values less than 0.05 were considered as statistically
significant. Analyses were performed with JMP software
(version 7.0.1, SAS, Cary, N.C.).
Results
Among 118 subjects included in the study, 19 (16%) had a
second IB inserted, either immediately after removal of the
first IB to prolong IB therapy (n=8), or after a IB-free
interval (n=11; median duration of the IB-free interval,
16.3 months [IQR, 7.1–28.4]). No significant difference
was found at baseline between groups of subjects who
finally received single or repeat IB insertion (Table 1). Two
thirds (13/19 [68%]) of repeat IB insertions were performed
during the year following first IB extraction.
Among factors available during initial IB therapy, the
only independent predictor of repeat treatment was a higher
weight loss at 3 months after IB insertion (Table 2). More
frequent visits with the dietician and a longer duration of IB
therapy were also associated with repeat treatment, but
these associations became weaker (P=0.142 and P=0.129,
respectively) after inclusion of weight loss 3 months after
first IB insertion.
Compared with first IB therapy, repeat treatment was
associated with a significantly smaller weight loss and a
trend toward more complications (Table 3). Lower weight
loss with the second IB was mainly related to the relatively
low weight loss that was observed in subjects who received
the second IB to prolong treatment with the first IB, as
opposed to subjects who received it after a IB-free interval
(Fig. 1). The latter subjects had regained 13.6 kg (IQR, 9.6–
22.5), corresponding to 28.4% excess weight (EW; IQR,
16.3–42.1), during the IB-free interval.
Figure 2 discloses a comparison of weight loss curves
after extraction of the first IB between the two groups of
subjects (treatment with one vs two IBs). During the first
2 years, weight regains were similar for both groups and the
curves were almost parallel; during the third year, weight
regain was more important in subjects treated with two IBs
vs one IB (4 [IQR, 0–15] vs 1 kg [IQR, 0–4], 9.6% EW
[IQR, 0–54.9] vs 3.1% EW [IQR, 0–10.9]; P=0.005) and
weight loss curves joined together at ≥3 years. Compared to
baseline, body weight was significantly lower up to 2 years
Single IB (n=99) Repeat IB (n=19) P value
Female sex - no. 82 (83%) 17 (89%) 0.735
Age (years) 39.0 (34.0–49.0) 37.0 (31.0–45.0) 0.412
Baseline weight (kg) 92.0 (84.0–105.0) 93.0 (85.7–97.0) 0.540
Baseline BMI (kg/m2) 34.0 (31.2–36.9) 31.9 (31.2–37.7) 0.767
Excess weight (kg) 33.8 (25.2–42.8) 31.0 (25.5–38.8) 0.663
Previous therapies—no.
Dietary guidance by a dietician 94 (95%) 18 (95%) 1
Structured weight loss program 56 (57%) 14 (74%) 0.207
Weight loss drugs 21 (21%) 5 (26%) 0.763
Comorbidities—no.
Dyslipidemia 25 (25%) 6 (32%) 0.577
Arterial hypertension 19 (19%) 1 (5%) 0.191
Osteoarthropathy 16 (16%) 3 (16%) 1
Diabetes mellitus 10 (10%) 2 (11%) 1
Sleep apnea 5 (5%) 0 1
Non-alcoholic steatohepatitis 1 (5%) 1 (1%) 0.297
Table 1 Subjects’ characteristics
at the time of first IB insertion
(n=118)
BMI body mass index, IB intra-
gastric balloon
Values with ranges are medians
with interquartile range in
parentheses
694 OBES SURG (2010) 20:692–697
post IB extraction in the group of subjects who had repeat
IB insertion (P<0.001 for both comparisons, at 1 and
2 years) and up to three years post IB extraction in the
group of subjects who received a single IB (P values for
comparison at 1, 2, and 3 years; <0.001, <0.001, and =0.001,
respectively). The proportion of subjects with ≥5% baseline
weight loss was significantly greater in the group of subjects
with repeat vs single IB therapy at 1 and 2 years post IB
extraction only (Fig. 3). At the end of follow-up (4.9 years;
IQR, 3.4–6.7), the proportions of subjects with≥5% and
with ≥10% baseline weight loss (and no bariatric surgery)
were 46/118 (39%) and 31/118 (26%), respectively.
During follow-up, 32% of subjects underwent bariatric
surgery after either single or repeat IB therapy (32/99 [32%]
vs 6/19 [32%], respectively; P=1). Bariatric surgery was
delayed in subjects with repeat vs those with single IB
therapy (interval between first IB insertion and surgery, 3.0
[IQR, 2.3–5.2] vs 2.2 years [IQR, 1.3–2.8], respectively;
P=0.016); at the time of surgery, weight regain since first
IB extraction tended to be higher in subjects with repeat vs
single IB therapy (19.0 [IQR, 8.3–30.0] vs 13.1 kg [IQR,
5.5–19.3]; 61.2% EW [IQR, 25.9–109.5] vs 34.4% EW
[IQR, 14.7–56.5]; P=0.097).
Complications with the second IB tended to be more
frequent compared to the first one (Table 3); they consisted
of esophagitis (n=2) and digestive intolerance that was treated
by early IB extraction (n=2) and IV drugs plus electrolyte
administration during a 2-day hospital stay (n=1).
Discussion
Repeating IB therapy at patient’s request was felt an
acceptable option to help patients maintaining weight loss
at long term (≥2 years); it was performed in a proportion of
subjects (16%) almost identical to those previously reported
without severe side-effect [8, 9]. However, this strategy
proved disappointing as, 3 years after extraction of the first
IB, weight loss curves and proportions of subjects with
≥10% baseline weight loss were almost identical for
subjects treated with single vs repeat IB insertion. These
results were observed despite the fact that IB therapy was
repeated in self-selected subjects who had experienced
superior weight loss with the first treatment (higher weight
loss 3 months after first IB insertion was the single
predictor of repeat IB therapy).
Even though repeating IB therapy in a subset of subjects
did not improve long-term results, these were not inferior to
those reported with alternative non-surgical weight loss
techniques. Our subjects who completed 5-year follow-up
had ≥10% and ≥5% baseline weight loss in 41% and 31%
of cases, respectively. This compares to fewer than 10% of
subjects with dietary/lifestyle weight reduction methods
(≥5% baseline weight loss at 4 years) and to 34–57% of
subjects treated with orlistat or sibutramine (≥5% baseline
weight loss at 2 years; present series, 49%) [10].
Few effective options are available to prevent weight
regain after any non-surgical weight loss intervention [11].
Variable P value
Higher weight loss 3 months after first IB insertion 0.008
Higher number of visits with the dietician during IB therapy 0.028
Longer duration of IB therapy 0.048
Intake of a fiber-enriched, fat restricted, diet during IB therapy 0.052
Performance of moderate-intensity exercise ≥ 30 min daily during IB therapy 0.152
Younger age 0.449
Female gender 0.515
Intake of weight loss drugs prior to IB therapy 0.659
Lower baseline BMI 0.851
Table 2 Logistic regression
analysis of variables associated
with repeat IB therapy
BMI body mass index, IB
intragastric balloon
First IB Second IB P value
BMI at IB insertion (kg/m2) 31.9 (31.2–37.7) 31.5 (28.1–34.5) 0.019
IB fill volume (ml) 500 (500–600) 600 (600–700) <0.001
Weight loss (kg) 14.6 (11.5–23.0) 9.0 (1.0–13.0) 0.003
Excess weight loss (%) 49.3 (27.2–61.0) 18.2 (2.4–42.1) 0.004
Complications—no. 2 (11%) 5 (26%) 0.375
Table 3 Comparison of first vs
second IB therapy (n=19)
BMI body mass index, IB intra-
gastric balloon
Values with ranges are medians
with interquartile range in
parentheses
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We had proposed no structured weight-maintenance pro-
gram to our subjects because we estimated that the cost-
benefit ratio of such programs was too high [12]. Instead,
we recommended monthly visits with the dietician for
6 months following IB removal, but a median of only one
visit was achieved. This had likely little or no impact on the
final results because a recent meta-analysis has found that,
during the maintenance phase of weight loss, the frequency
of meetings of dietary counseling was not predictive of
weight change (contrary to that being predictive during the
active weight loss phase) [11]. Combination of IB therapy
with weight loss drugs is another option to help maintaining
weight loss: a 6-month course of sibutramine following IB
extraction has allowed to decrease weight regain at 1 year
by 5 kg compared to controls (P<0.001) [13]. However,
major problems with weight loss drugs include the extremely
high attrition rates (>90% in common clinical practice,
40–50% in clinical trials) [14, 15] and short durations of
approved treatment (1 and 2 years for orlistat and sibutr-
amine, respectively) [16].
After a median follow-up of 5 years, bariatric surgery
had been performed in an equally high proportion of
subjects after single vs repeat IB therapy (32%). Repeat IB
therapy was associated with a longer delay and a higher
weight regain before recourse to bariatric surgery. As
reported by Melissas [17], temporary weight loss associated
with IB therapy and related benefits likely facilitated the
election of bariatric surgery by some of our subjects who
initially refused bariatric surgery. Hence, for a significant
proportion of subjects, the IB can be viewed as a stage in
the patient's quest for weight stabilization. However, it
should be clear that surgeons have to stick upon interna-
tional guidelines with regard to indications for bariatric
surgery, and should refuse “cosmetic” indications. This was
not the case for a significant proportion of our patients, who
underwent bariatric surgery outside of our institutions.
In subjects who requested to prolong IB therapy, we
exchanged the IB because treatment with the same IB for
periods >6 months has been associated with high rates of
spontaneous IB migration (19–28%) [18, 19] that may
cause small bowel obstruction requiring surgery [19–21].
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Fig. 2 Comparison of weight loss from baseline in the two groups of
subjects (treatment with one vs two intragastric balloons [IB]). Last
observation carried forward analysis. *P<0.05. **P<0.01 for com-
parison between groups. Median excess weight losses in subjects who
received one vs two IBs, respectively, were, at IB extraction, 30.7%
(IQR, 18.6–44.2) vs 49.3% (IQR, 27.2–61.0) and, at 5 years, 4.6%
(IQR, −15.2 to 30.6) vs 2.6% (IQR, −11.2 to 30.6)
Fig. 1 Weight loss observed with the second intragastric balloon (IB).
Box-whisker graph of weight loss observed during treatment with the
second IB in subjects who received the second IB immediately after
extraction of the first one (n=8) or after a IB-free interval (n=11).
Each box represents the interquartile range (between Q1 and Q3); the
horizontal line across the box represents the median value; the vertical
lines extend from the box to the lowest and highest values. Median
excess weight losses were 4.1% (IQR, 16.3–42.1) and 28.5% (IQR,
16.3–42.1) for subjects who received the second IB immediately after
extraction of the first one or after a IB-free interval, respectively
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Fig. 3 Percentages of subjects with ≥5% and with ≥10% baseline
weight loss. For each time point, the higher and the lower bars
indicate the percentage of subjects with ≥5% and with ≥10% baseline
weight loss, respectively, for subjects treated with one vs two
intragastric balloons (IB). Last observation carried forward analysis.
*P<0.05 for comparison of subjects treated with one vs two IBs
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Filling the IB with a small amount of methylene blue is
common practice to detect IB leakage early (through
staining of the urines), and ultrasound examination at
regular intervals has also been proposed for this purpose
[9]. However, all these measures do not allow avoiding
intestinal occlusion, even with the current generation of
IB [9].
The main limitation of our study is the relatively small
number of subjects who underwent repeat IB therapy. The
choice of performing repeat IB insertion at patient’s request
and not in all patients, as previously reported [4], or in a
randomized manner was dictated by the vanishing of IB-
related effects on appetite and satiety in a majority of
patients. A sham-controlled study has found that the IB
decreased appetite and increased satiety at 4 weeks, but
not at 12 weeks, post insertion [3]. However, as only 11
subjects received an IB in that study, a type II statistical
error cannot be excluded. Indeed, in our study, subjects
who requested for “IB exchange” at the theoretical date of
IB extraction were still experiencing IB effects on appetite
and satiety, and they estimated that modifications of their
eating habits were too frail. On the other hand, subjects
who requested repeat treatment after a IB-free interval had
incurred a weight regain of almost 14 kg before repeat IB
insertion, and this was performed as a “second chance” to
modify their eating habits more durably. Conversely, the
main strengths of our series include unique follow-up
duration and our absence of relationship with the weight
loss industry.
In conclusion, repeating IB therapy at subjects’ request
to help maintaining weight loss only had a temporary
effect. It did not yield greater weight loss starting at 3 years
of follow-up and it did not decrease recourse to bariatric
surgery, which was relatively common.
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